Webinar on Best Practices and the FDA’s Abuse-Deterrent Guidance for Innovator and Generic Opioids
Featured speakers include:
Daniel Leach, B.Sc (Hons), Director of Pharmaceutical Services DRUGSCAN, Inc.
Edward Cone, Ph.D., Principal Scientist, Drug Delivery and Abuse-Deterrent Drug Products, PinneyAssociates.
Beatrice Setnik, Ph.D., Vice President of Clinical Pharmacology Early Phase, INC Research.
Describe the similarities and differences between the FDA’s innovator and generic guidance for abuse-deterrent opioids and their target audiences
Review best practices for conducting studies to evaluate abuse resistance and abuse potential.